Genmab ADR

GMABNASDAQ · USD
50.60USD0.00 (-1.47%)
9610

Genmab ADR (GMAB) Covered Calls

Genmab ADR trades in the Biotechnology industry with an IV Rank of 18.65%, low versus the past year. GMAB's highest covered call setup is the $65.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 28.46% out of the money with 28 days to expiration, a 28.56% return until expiration, and a 372.26% theoretical annualized return. Across the setups shown, annualized returns run from 74.71% to 372.26% at strikes between $55.00 and $75.00, with 28 to 182 days to expiration, as of Nov 20, 2026.

Read more

Running GMAB covered calls helps you generate income from Genmab ADR shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best GMAB covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If GMAB stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling GMAB covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given GMAB covered call is worth writing.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies.

2026-12-182865.0028.460.050.201445.0028.56372.26-0.10+0.055,3940.15
2026-12-182860.0018.580.200.60960.0018.97247.32-0.40+0.124,6420.40
2027-01-155665.0028.460.200.701460.0028.85188.06-0.40+0.118980.50
2026-12-182855.008.700.750.95515.0010.18132.68-1.48+0.264510.20
2027-01-155660.0018.580.251.35965.0019.07124.30-0.49+0.194,1051.10
2027-02-199165.0028.460.551.301495.0029.55118.51-1.09+0.173790.75
2027-05-2118275.0048.220.251.402465.0048.7297.70-0.49+0.1311.15
2027-02-199160.0018.580.952.001035.0020.4582.04-1.88+0.261171.05
2027-05-2118270.0038.340.701.902010.0039.7279.66-1.38+0.1811.20
2027-01-155655.008.701.402.40580.0011.4674.71-2.77+0.367941.00

As of Nov 20, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank18.65% Low
  • Market cap (M$)31,199
  • 52 weeks high-15.62%
  • 52 weeks low114.23%
  • Analyst recommendationBuy
    1.64
  • Target price$64.39
    27.25% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2027-02-16
  • P/E43.36
  • Future P/E31.58
  • EPS (ttm)1.17
  • EPS growth next 5 years20.35%

As of Nov 20, 2026